New lupus drug YK012 enters human trials – hope for patients?

NCT ID NCT07010835

Recruiting now Disease control Sponsor: Excyte Biopharma Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug, YK012, in people with moderate to severe systemic lupus erythematosus (SLE). The drug is designed to target certain immune cells. The trial will check for safety, side effects, and early signs that the drug might help control lupus. About 189 adults aged 18 to 75 are being recruited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YK012 (a bispecific antibody that targets CD19 and CD3 on immune cells)
What this could lead to: If it works, this could point toward a new treatment option for people with moderate to severe lupus, potentially helping to control the disease.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 189 participants, so it is too soon to know if YK012 is safe or effective. Side effects, including serious ones, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.